Author: Ravi Shankar

SINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) — From September 24 to 25, the Tourism EXPO Japan 2026 took place at Tokyo Big Sight. Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services, was invited to co-exhibit as a sponsor of the Japan Web3 Tourism Association, demonstrating how AI technology is empowering the digital transformation of the tourism sector.

The Tourism Paradox: Booming Inbound Travel vs. Overstretched Staff
As inbound tourism to Japan reaches record highs, the industry is grappling with an unprecedented staffing crisis. Throughout the exhibition, frontline hospitality professionals voiced consistent operational frustrations: the inability to manage overnight inquiry backlogs, severe front-desk bottlenecks caused by language barriers with non-English-speaking groups, and a lack of manpower to produce dynamic video content for international marketing.

These challenges illustrate that the tourism sector’s demand for AI has moved far beyond basic chatbots. What is urgently needed are “digital employees” capable of handling real workloads and executing complex operations.

Live on Site: AI Solutions Integrated into Real Workflows
At this exhibition, the Aurora Mobile Japan team presented EngageLab (customer engagement platform), GPTBots.ai (enterprise-grade AI agent platform), and Modellix.ai (unified AI media generation platform), conducting live demonstrations tailored to tourism scenarios:

• Moving Beyond Translation Apps with 24/7 Multilingual AI Guides: By scanning QR codes at scenic spots or hotels, tourists can converse smoothly with AI in their native language (supporting 100+ languages). Whether searching for local cuisine or booking unique experiences, the AI provides precise recommendations based on real-time operational status and seamlessly guides the user to complete the booking process.
• Alleviating Customer Service Overload via EngageLab LiveDesk and GPTBots.ai: For high-frequency standard inquiries like “Are you open today?” or “Where is the parking lot?” as well as after-hours support gaps, AI Agents powered by GPTBots.ai provide 24/7 precise automated responses. When encountering highly complex or personalized needs, the system seamlessly routes the conversation to human agents via EngageLab LiveDesk. This efficient collaboration between AI agents and human staff within a single platform ensures an uninterrupted traveler experience while significantly reducing the strain on frontline employees.
• Eliminating Tedious Editing as Modellix.ai Brings Landscape Photos to Life: Addressing the promotional bottlenecks of local tourism boards and hotels, the site showcased Modellix.ai’s video generation capabilities. By simply uploading a few static landscape or hotel room photos—and without needing a professional editing team—the AI automatically generates exquisite PR videos ready for social media distribution.

From Standalone Tools to End-to-End Workflows
As we have consistently emphasized at previous exhibitions, what enterprises truly need is not just another isolated AI tool, but a practical starting point that integrates smoothly into existing workflows. At this event, Aurora Mobile showcased not only cutting-edge technology but also deep synergy with current tourism service systems—allowing AI to handle standardized, high-frequency tasks, and freeing humans to provide deeper, more empathetic hospitality.

Moving forward, Aurora Mobile will continue to deepen its localized support, helping the global tourism industry accelerate its embrace of digital transformation.

About EngageLab
EngageLab is an AI-first customer engagement platform that helps you build stronger customer relationships with AI agents, unified customer data, and reliable delivery across channels.

EngageLab’s global customers include Dhgate, HelloRide, The Consejo Nacional Electoral (CNE) of Ecuador, J&T Cargo, Blurams and many more.

For more information, please contact: marketing@engagelab.com

About GPTBots.ai
GPTBots.ai is an enterprise-grade AI agent platform under Aurora Mobile (NASDAQ: JG), offering no-code/low-code AI agent development, deployment, and management for enterprise clients. Through multi-model LLM integration and intelligent workflow automation, GPTBots.ai empowers organizations to enhance customer service, optimize knowledge management, and automate business processes, driving digital innovation and transformation worldwide.

GPTBots.ai’s global customers include Axios Management, GP Batteries, Echosens China, and many more.

For more information, please contact: marketing@gptbots.ai

About Modellix
Modellix is Aurora Mobile’s premier unified platform for AI media generation. It enables developers and enterprises to generate, track, and scale content using world-class models through a single, secure, and transparent API.

For more information, please contact: marketing@modellix.ai

About Aurora Mobile
Founded in 2011, Aurora Mobile (NASDAQ: JG) is a leading provider of customer engagement and marketing technology services. The Company is dedicated to empowering global enterprises with stable, efficient, and intelligent customer interaction solutions. Leveraging its first-mover advantage in mobile messaging, Aurora Mobile has evolved into a comprehensive platform that integrates Omnichannel Engagement, AI-Driven Marketing, Advanced AI Customer Support, and Frictionless Identity Security. Through its flagship brand EngageLab and its robust AI infrastructure GPTBots.ai, the Company helps businesses achieve seamless customer reach, automate complex marketing journeys, and optimize service efficiency with AI agents, accelerating digital transformation for clients worldwide.

For more information, please visit: https://ir.aurora-mobile.com/

Media contact: marketing@aurora-mobile.com

Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as Aurora Mobile’s strategic and operational plans, contain forward-looking statements. Aurora Mobile may also make written or oral forward-looking statements in its reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Aurora Mobile’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Aurora Mobile’s strategies; Aurora Mobile’s future business development, financial condition and results of operations; Aurora Mobile’s ability to attract and retain customers; its ability to develop and effectively market data solutions, and penetrate the existing market for developer services; its ability to transition to the new advertising-driven SAAS business model; its ability to maintain or enhance its brand; the competition with current or future competitors; its ability to continue to gain access to mobile data in the future; the laws and regulations relating to data privacy and protection; general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and Aurora Mobile undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:
Aurora Mobile Limited
E-mail: ir@aurora-mobile.com

Christensen Advisory
Ms. Xiaoyan Su
E-mail: Xiaoyan.Su@christensencomms.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7ec171bc-8971-4167-8b83-6f8d0c56a7b5

SINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) — From September 24 to 25, the Tourism EXPO Japan 2026 took place at Tokyo Big Sight. Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services, was invited to co-exhibit as a sponsor of the Japan Web3 Tourism Association, demonstrating how AI technology is empowering the digital transformation of the tourism sector.

The Tourism Paradox: Booming Inbound Travel vs. Overstretched Staff
As inbound tourism to Japan reaches record highs, the industry is grappling with an unprecedented staffing crisis. Throughout the exhibition, frontline hospitality professionals voiced consistent operational frustrations: the inability to manage overnight inquiry backlogs, severe front-desk bottlenecks caused by language barriers with non-English-speaking groups, and a lack of manpower to produce dynamic video content for international marketing.

These challenges illustrate that the tourism sector’s demand for AI has moved far beyond basic chatbots. What is urgently needed are “digital employees” capable of handling real workloads and executing complex operations.

Live on Site: AI Solutions Integrated into Real Workflows
At this exhibition, the Aurora Mobile Japan team presented EngageLab (customer engagement platform), GPTBots.ai (enterprise-grade AI agent platform), and Modellix.ai (unified AI media generation platform), conducting live demonstrations tailored to tourism scenarios:

• Moving Beyond Translation Apps with 24/7 Multilingual AI Guides: By scanning QR codes at scenic spots or hotels, tourists can converse smoothly with AI in their native language (supporting 100+ languages). Whether searching for local cuisine or booking unique experiences, the AI provides precise recommendations based on real-time operational status and seamlessly guides the user to complete the booking process.
• Alleviating Customer Service Overload via EngageLab LiveDesk and GPTBots.ai: For high-frequency standard inquiries like “Are you open today?” or “Where is the parking lot?” as well as after-hours support gaps, AI Agents powered by GPTBots.ai provide 24/7 precise automated responses. When encountering highly complex or personalized needs, the system seamlessly routes the conversation to human agents via EngageLab LiveDesk. This efficient collaboration between AI agents and human staff within a single platform ensures an uninterrupted traveler experience while significantly reducing the strain on frontline employees.
• Eliminating Tedious Editing as Modellix.ai Brings Landscape Photos to Life: Addressing the promotional bottlenecks of local tourism boards and hotels, the site showcased Modellix.ai’s video generation capabilities. By simply uploading a few static landscape or hotel room photos—and without needing a professional editing team—the AI automatically generates exquisite PR videos ready for social media distribution.

From Standalone Tools to End-to-End Workflows
As we have consistently emphasized at previous exhibitions, what enterprises truly need is not just another isolated AI tool, but a practical starting point that integrates smoothly into existing workflows. At this event, Aurora Mobile showcased not only cutting-edge technology but also deep synergy with current tourism service systems—allowing AI to handle standardized, high-frequency tasks, and freeing humans to provide deeper, more empathetic hospitality.

Moving forward, Aurora Mobile will continue to deepen its localized support, helping the global tourism industry accelerate its embrace of digital transformation.

About EngageLab
EngageLab is an AI-first customer engagement platform that helps you build stronger customer relationships with AI agents, unified customer data, and reliable delivery across channels.

EngageLab’s global customers include Dhgate, HelloRide, The Consejo Nacional Electoral (CNE) of Ecuador, J&T Cargo, Blurams and many more.

For more information, please contact: marketing@engagelab.com

About GPTBots.ai
GPTBots.ai is an enterprise-grade AI agent platform under Aurora Mobile (NASDAQ: JG), offering no-code/low-code AI agent development, deployment, and management for enterprise clients. Through multi-model LLM integration and intelligent workflow automation, GPTBots.ai empowers organizations to enhance customer service, optimize knowledge management, and automate business processes, driving digital innovation and transformation worldwide.

GPTBots.ai’s global customers include Axios Management, GP Batteries, Echosens China, and many more.

For more information, please contact: marketing@gptbots.ai

About Modellix
Modellix is Aurora Mobile’s premier unified platform for AI media generation. It enables developers and enterprises to generate, track, and scale content using world-class models through a single, secure, and transparent API.

For more information, please contact: marketing@modellix.ai

About Aurora Mobile
Founded in 2011, Aurora Mobile (NASDAQ: JG) is a leading provider of customer engagement and marketing technology services. The Company is dedicated to empowering global enterprises with stable, efficient, and intelligent customer interaction solutions. Leveraging its first-mover advantage in mobile messaging, Aurora Mobile has evolved into a comprehensive platform that integrates Omnichannel Engagement, AI-Driven Marketing, Advanced AI Customer Support, and Frictionless Identity Security. Through its flagship brand EngageLab and its robust AI infrastructure GPTBots.ai, the Company helps businesses achieve seamless customer reach, automate complex marketing journeys, and optimize service efficiency with AI agents, accelerating digital transformation for clients worldwide.

For more information, please visit: https://ir.aurora-mobile.com/

Media contact: marketing@aurora-mobile.com

Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as Aurora Mobile’s strategic and operational plans, contain forward-looking statements. Aurora Mobile may also make written or oral forward-looking statements in its reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Aurora Mobile’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Aurora Mobile’s strategies; Aurora Mobile’s future business development, financial condition and results of operations; Aurora Mobile’s ability to attract and retain customers; its ability to develop and effectively market data solutions, and penetrate the existing market for developer services; its ability to transition to the new advertising-driven SAAS business model; its ability to maintain or enhance its brand; the competition with current or future competitors; its ability to continue to gain access to mobile data in the future; the laws and regulations relating to data privacy and protection; general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and Aurora Mobile undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:
Aurora Mobile Limited
E-mail: ir@aurora-mobile.com

Christensen Advisory
Ms. Xiaoyan Su
E-mail: Xiaoyan.Su@christensencomms.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7ec171bc-8971-4167-8b83-6f8d0c56a7b5

HOUSTON and LONDON, Sept. 28, 2026 (GLOBE NEWSWIRE) — Baker Hughes (NASDAQ: BKR) will announce the results of the third quarter ending Sept. 30, 2026, via press release at 5 p.m. Eastern Time (4 p.m. Central Time) on Tuesday, Oct. 27, 2026. A webcast to discuss the results will be held Wednesday, Oct. 28, 2026, at 9:30 a.m. Eastern Time (8:30 a.m. Central Time).

To access the webcast, listeners should visit the Baker Hughes website at: investors.bakerhughes.com. An archived version will be available on the website following the webcast.

About Baker Hughes
Baker Hughes (NASDAQ: BKR) is an energy technology company that provides solutions to energy and industrial customers worldwide. Built on a century of experience and conducting business in over 120 countries, our innovative technologies and services are taking energy forward – making it safer, cleaner and more efficient for people and the planet. Visit us at bakerhughes.com.

For more information, please contact:

Investor Relations
Chase Mulvehill
+1 346-297-2561
investor.relations@bakerhughes.com

Media Relations
Adrienne M. Lynch
+1 713-906-8407
media.relations@bakerhughes.com

HOUSTON and LONDON, Sept. 28, 2026 (GLOBE NEWSWIRE) — Baker Hughes (NASDAQ: BKR) will announce the results of the third quarter ending Sept. 30, 2026, via press release at 5 p.m. Eastern Time (4 p.m. Central Time) on Tuesday, Oct. 27, 2026. A webcast to discuss the results will be held Wednesday, Oct. 28, 2026, at 9:30 a.m. Eastern Time (8:30 a.m. Central Time).

To access the webcast, listeners should visit the Baker Hughes website at: investors.bakerhughes.com. An archived version will be available on the website following the webcast.

About Baker Hughes
Baker Hughes (NASDAQ: BKR) is an energy technology company that provides solutions to energy and industrial customers worldwide. Built on a century of experience and conducting business in over 120 countries, our innovative technologies and services are taking energy forward – making it safer, cleaner and more efficient for people and the planet. Visit us at bakerhughes.com.

For more information, please contact:

Investor Relations
Chase Mulvehill
+1 346-297-2561
investor.relations@bakerhughes.com

Media Relations
Adrienne M. Lynch
+1 713-906-8407
media.relations@bakerhughes.com

– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors –

NEW HAVEN, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the first participant has been dosed in its Phase 1/2 clinical trial of ARV-6723, an investigational, oral PROteolysis TArgeting Chimera (PROTAC) designed to degrade hematopoietic progenitor kinase 1 (HPK1) in advanced solid tumors. ARV-6723 is Arvinas’ first clinical candidate in immuno-oncology (IO) and the first HPK1 PROTAC degrader to enter the clinic in the United States.

HPK1 acts as a negative regulator of immune activation and is expressed across multiple cell types including T cells, B cells, natural killer cells, and dendritic cells, making it a compelling IO target. HPK1 also plays an important role in shaping the tumor microenvironment. ARV-6723 is designed to degrade and remove the HPK1 protein and its signaling scaffolding, potentially addressing functions of HPK1 that may not be fully addressed by traditional inhibitors.

In preclinical studies, ARV-6723 demonstrated potent and selective HPK1 degradation, enhanced immune activity, and antitumor activity as a single agent and in combination with an immune checkpoint inhibitor across tumor models with differing levels of immune responsiveness, including multiple anti-PD-1-resistant models. Notably, in seven preclinical models, ARV-6723 demonstrated meaningful single-agent activity where neither an HPK1 inhibitor nor anti-PD-1 therapy showed benefit. These data support the clinical evaluation of ARV-6723 both as monotherapy and in combination with an anti-PD-1 therapy.

“The advancement of ARV-6723 into the clinic represents an important step in expanding the application of targeted protein degradation into immuno-oncology,” said Randy Teel, Ph.D., President and Chief Executive Officer at Arvinas. “Resistance to immunotherapy remains a significant challenge; to date, combinations targeting other immune pathways have not provided a reliable way to prevent or reverse it. The encouraging preclinical data for ARV-6723 – including activity in models resistant to immune checkpoint inhibitors – support clinical investigation of its potential to address this unmet need for patients.”

The ARV-6723-101 Phase 1/2 clinical trial (NCT07749586) is a global, multicenter trial designed to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of orally administered ARV-6723 as a monotherapy or in combination with pembrolizumab in adults with advanced solid tumors. The first-in-human trial will initially evaluate the safety of ARV-6723 as a monotherapy treatment and subsequently in combination with an anti-PD-1 therapy, while also evaluating whether deep and sustained HPK1 degradation translates into meaningful antitumor effects in patients. The initial monotherapy cohort of this trial is enrolling patients who have received a prior immune checkpoint inhibitor and have no suitable standard treatment options.

About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas, with its partner Pfizer, developed the first U.S. Food and Drug Administration (FDA)-approved PROTAC, a type of heterobifunctional protein degrader, which has been outlicensed to Rigel Pharmaceuticals, Inc. for exclusive global development, manufacturing, and commercialization.

Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal-bulbar muscular atrophy, also known as Kennedy’s disease; and ARV-6723, targeting HPK1 for advanced solid tumors. Arvinas has also advanced ARV-806, targeting KRAS G12D for solid tumors, in the clinic, and previously announced plans to seek an out-licensing agreement for any additional clinical trials of ARV-806, including dose expansion or combination clinical trials. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

About ARV-6723
ARV-6723 is an investigational, oral PROTAC designed to degrade hematopoietic progenitor kinase 1 (HPK1) and is Arvinas’ first clinical candidate in the immuno-oncology space. HPK1 is a negative regulator of immune activation expressed across multiple immune cell types, including T cells, B cells, natural killer cells, and dendritic cells. Preclinically, ARV-6723 demonstrated potent, selective HPK1 degradation and greater tumor growth inhibition across low- and high-immunogenic tumor models, including anti-PD-1 resistant tumor models. By removing HPK1, ARV-6723 may address both its kinase-dependent and kinase-independent functions and enhance antitumor immune activity. ARV-6723 is currently being evaluated in a first-in-human Phase 1/2 clinical trial in patients with advanced solid tumors.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the potential of ARV-6723, including its degradation of hematopoietic progenitor kinase 1 (“HPK1”), and its potential treatment of advanced solid tumors; whether by removing HPK1, ARV-6723 may address both its kinase-dependent and kinase-independent functions and enhance antitumor immune activity; preclinical ARV-6723 data supporting the clinical evaluation of ARV-6723 both as monotherapy and in combination with an anti-PD-1 therapy; whether ARV-6723’s design to degrade and remove the HPK1 protein and its signaling scaffolding will address functions of HPK1 that may not be fully addressed by traditional inhibitors; Arvinas’ plans with respect to ARV-6723 and its development; and Arvinas’ plans to outlicense ARV-806. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas’ strategy, development plans, future operations, prospects, plans, and objectives of management and the statements identified in the prior paragraph, are forward-looking statements. The words “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “target,” “goal,” “aim,” “whether,” “will,” “would,” “could,” “reliance,” “should,” “look forward,” “seek,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Arvinas may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas will be able to successfully conduct and complete development for its product candidates, including ARV-6723, on its current timelines or at all; risks related to clinical trial results and the interpretation thereof, including with respect to ARV-6723; that the results of preclinical studies may not be predictive of the results of clinical trials; Arvinas’ ability to protect its intellectual property portfolio; Arvinas’ reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas’ cash and cash equivalents will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent other reports filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release.

Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com

– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors –

NEW HAVEN, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the first participant has been dosed in its Phase 1/2 clinical trial of ARV-6723, an investigational, oral PROteolysis TArgeting Chimera (PROTAC) designed to degrade hematopoietic progenitor kinase 1 (HPK1) in advanced solid tumors. ARV-6723 is Arvinas’ first clinical candidate in immuno-oncology (IO) and the first HPK1 PROTAC degrader to enter the clinic in the United States.

HPK1 acts as a negative regulator of immune activation and is expressed across multiple cell types including T cells, B cells, natural killer cells, and dendritic cells, making it a compelling IO target. HPK1 also plays an important role in shaping the tumor microenvironment. ARV-6723 is designed to degrade and remove the HPK1 protein and its signaling scaffolding, potentially addressing functions of HPK1 that may not be fully addressed by traditional inhibitors.

In preclinical studies, ARV-6723 demonstrated potent and selective HPK1 degradation, enhanced immune activity, and antitumor activity as a single agent and in combination with an immune checkpoint inhibitor across tumor models with differing levels of immune responsiveness, including multiple anti-PD-1-resistant models. Notably, in seven preclinical models, ARV-6723 demonstrated meaningful single-agent activity where neither an HPK1 inhibitor nor anti-PD-1 therapy showed benefit. These data support the clinical evaluation of ARV-6723 both as monotherapy and in combination with an anti-PD-1 therapy.

“The advancement of ARV-6723 into the clinic represents an important step in expanding the application of targeted protein degradation into immuno-oncology,” said Randy Teel, Ph.D., President and Chief Executive Officer at Arvinas. “Resistance to immunotherapy remains a significant challenge; to date, combinations targeting other immune pathways have not provided a reliable way to prevent or reverse it. The encouraging preclinical data for ARV-6723 – including activity in models resistant to immune checkpoint inhibitors – support clinical investigation of its potential to address this unmet need for patients.”

The ARV-6723-101 Phase 1/2 clinical trial (NCT07749586) is a global, multicenter trial designed to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of orally administered ARV-6723 as a monotherapy or in combination with pembrolizumab in adults with advanced solid tumors. The first-in-human trial will initially evaluate the safety of ARV-6723 as a monotherapy treatment and subsequently in combination with an anti-PD-1 therapy, while also evaluating whether deep and sustained HPK1 degradation translates into meaningful antitumor effects in patients. The initial monotherapy cohort of this trial is enrolling patients who have received a prior immune checkpoint inhibitor and have no suitable standard treatment options.

About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas, with its partner Pfizer, developed the first U.S. Food and Drug Administration (FDA)-approved PROTAC, a type of heterobifunctional protein degrader, which has been outlicensed to Rigel Pharmaceuticals, Inc. for exclusive global development, manufacturing, and commercialization.

Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal-bulbar muscular atrophy, also known as Kennedy’s disease; and ARV-6723, targeting HPK1 for advanced solid tumors. Arvinas has also advanced ARV-806, targeting KRAS G12D for solid tumors, in the clinic, and previously announced plans to seek an out-licensing agreement for any additional clinical trials of ARV-806, including dose expansion or combination clinical trials. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

About ARV-6723
ARV-6723 is an investigational, oral PROTAC designed to degrade hematopoietic progenitor kinase 1 (HPK1) and is Arvinas’ first clinical candidate in the immuno-oncology space. HPK1 is a negative regulator of immune activation expressed across multiple immune cell types, including T cells, B cells, natural killer cells, and dendritic cells. Preclinically, ARV-6723 demonstrated potent, selective HPK1 degradation and greater tumor growth inhibition across low- and high-immunogenic tumor models, including anti-PD-1 resistant tumor models. By removing HPK1, ARV-6723 may address both its kinase-dependent and kinase-independent functions and enhance antitumor immune activity. ARV-6723 is currently being evaluated in a first-in-human Phase 1/2 clinical trial in patients with advanced solid tumors.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the potential of ARV-6723, including its degradation of hematopoietic progenitor kinase 1 (“HPK1”), and its potential treatment of advanced solid tumors; whether by removing HPK1, ARV-6723 may address both its kinase-dependent and kinase-independent functions and enhance antitumor immune activity; preclinical ARV-6723 data supporting the clinical evaluation of ARV-6723 both as monotherapy and in combination with an anti-PD-1 therapy; whether ARV-6723’s design to degrade and remove the HPK1 protein and its signaling scaffolding will address functions of HPK1 that may not be fully addressed by traditional inhibitors; Arvinas’ plans with respect to ARV-6723 and its development; and Arvinas’ plans to outlicense ARV-806. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas’ strategy, development plans, future operations, prospects, plans, and objectives of management and the statements identified in the prior paragraph, are forward-looking statements. The words “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “target,” “goal,” “aim,” “whether,” “will,” “would,” “could,” “reliance,” “should,” “look forward,” “seek,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Arvinas may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas will be able to successfully conduct and complete development for its product candidates, including ARV-6723, on its current timelines or at all; risks related to clinical trial results and the interpretation thereof, including with respect to ARV-6723; that the results of preclinical studies may not be predictive of the results of clinical trials; Arvinas’ ability to protect its intellectual property portfolio; Arvinas’ reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas’ cash and cash equivalents will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent other reports filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release.

Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com

LONDON and RIYADH, Saudi Arabia, Sept. 28, 2026 (GLOBE NEWSWIRE) — Virtu Financial, Inc. (NYSE: VIRT), a leading provider of global, multi-asset financial services that delivers liquidity and innovative, transparent products across the complete investment cycle to global markets, today announced the launch of POSIT^® block-trading indications network for equity securities listed on the Saudi Exchange.

The addition of 245 of the most liquid Saudi Exchange-listed securities to the POSIT block-trading indications network gives Saudi Exchange members and their institutional clients access to Virtu’s established global network for sourcing block liquidity via Al Rajhi Capital, Virtu’s regional partner. Saudi Exchange members and their clients will be offered aggregation capabilities when accessing the POSIT block-trading indications network to further enhance workflow for investors.

Using the Negotiated Deals facility of the Saudi Exchange gives exchange members greater flexibility to execute large transactions on-platform. Virtu is leveraging the Saudi Exchange’s fully electronic Negotiated Deals facility to enable the completion of the block trades sourced through the POSIT system. All trades will settle on a T+2 basis through The Securities Depository Center Company (Edaa) — the standard settlement cycle used for Saudi Exchange trades. For firms that are not direct Saudi Exchange members, connectivity, brokerage, and post-trade services are provided by Al Rajhi Capital.

Mohammed Al-Rumaih, Chief Executive Officer of the Saudi Exchange said, “The integration of Saudi-listed securities into global institutional trading workflows reflects the continued evolution of the Saudi Capital Market and its increasing connectivity with international investors. At Saudi Exchange, we have consistently invested in market infrastructure, accessibility and efficiency, and we welcome developments that complement these efforts by providing institutional investors with additional ways to source liquidity and participate in our market.”

“Deploying POSIT technologies to Saudi-listed securities further enhances the appeal and accessibility of Saudi equity capital markets to global institutional investors,” said Rob Boardman, CEO of Virtu Execution Services, EMEA. “This initiative would have been impossible without the innovation and assistance provided by the Saudi Exchange and our local partners Al Rajhi Capital and Arqaam Capital.”

“Availability of block liquidity can lower the implementation cost of equity transactions, which benefits our clients, so we are pleased to use the new POSIT facility” said Graham Sorrell, Head of EMEA & APAC Equity and Currency Trading at State Street Investment Management, which conducted the first transaction on the platform. “This exciting development for the region speaks to the rapid evolution of the Kingdom’s market infrastructure and clearly demonstrates growing appeal of the Saudi market as a destination for capital and increased innovation in the market.”

“At Al Rajhi Capital we value partnerships very highly,” said Hossam Basrawi, Chief Executive Officer at Al Rajhi Capital. “We are delighted to participate in the launch of POSIT for Saudi equities in partnership with Virtu. This effort reflects our commitment to developing the electronic trading ecosystem of Saudi Arabia and providing institutional investors with world-class trading solutions.”

About Virtu Financial
Virtu Financial is comprised of companies and financial services firms that leverage cutting-edge technology to deliver liquidity to the global markets and innovative, transparent trading solutions to our clients. Virtu operates one of the world’s longest-running and most widely used electronic block-trading networks, serving institutional asset managers globally. For more information about Virtu’s POSIT block indications network and other workflow tools, please visit our client solutions page at virtu.com.

For more information, please contact:
Matt Sandberg
Investor Relations
investor_relations@virtu.com

Petri Darby
Media
media@virtu.com

LONDON and RIYADH, Saudi Arabia, Sept. 28, 2026 (GLOBE NEWSWIRE) — Virtu Financial, Inc. (NYSE: VIRT), a leading provider of global, multi-asset financial services that delivers liquidity and innovative, transparent products across the complete investment cycle to global markets, today announced the launch of POSIT^® block-trading indications network for equity securities listed on the Saudi Exchange.

The addition of 245 of the most liquid Saudi Exchange-listed securities to the POSIT block-trading indications network gives Saudi Exchange members and their institutional clients access to Virtu’s established global network for sourcing block liquidity via Al Rajhi Capital, Virtu’s regional partner. Saudi Exchange members and their clients will be offered aggregation capabilities when accessing the POSIT block-trading indications network to further enhance workflow for investors.

Using the Negotiated Deals facility of the Saudi Exchange gives exchange members greater flexibility to execute large transactions on-platform. Virtu is leveraging the Saudi Exchange’s fully electronic Negotiated Deals facility to enable the completion of the block trades sourced through the POSIT system. All trades will settle on a T+2 basis through The Securities Depository Center Company (Edaa) — the standard settlement cycle used for Saudi Exchange trades. For firms that are not direct Saudi Exchange members, connectivity, brokerage, and post-trade services are provided by Al Rajhi Capital.

Mohammed Al-Rumaih, Chief Executive Officer of the Saudi Exchange said, “The integration of Saudi-listed securities into global institutional trading workflows reflects the continued evolution of the Saudi Capital Market and its increasing connectivity with international investors. At Saudi Exchange, we have consistently invested in market infrastructure, accessibility and efficiency, and we welcome developments that complement these efforts by providing institutional investors with additional ways to source liquidity and participate in our market.”

“Deploying POSIT technologies to Saudi-listed securities further enhances the appeal and accessibility of Saudi equity capital markets to global institutional investors,” said Rob Boardman, CEO of Virtu Execution Services, EMEA. “This initiative would have been impossible without the innovation and assistance provided by the Saudi Exchange and our local partners Al Rajhi Capital and Arqaam Capital.”

“Availability of block liquidity can lower the implementation cost of equity transactions, which benefits our clients, so we are pleased to use the new POSIT facility” said Graham Sorrell, Head of EMEA & APAC Equity and Currency Trading at State Street Investment Management, which conducted the first transaction on the platform. “This exciting development for the region speaks to the rapid evolution of the Kingdom’s market infrastructure and clearly demonstrates growing appeal of the Saudi market as a destination for capital and increased innovation in the market.”

“At Al Rajhi Capital we value partnerships very highly,” said Hossam Basrawi, Chief Executive Officer at Al Rajhi Capital. “We are delighted to participate in the launch of POSIT for Saudi equities in partnership with Virtu. This effort reflects our commitment to developing the electronic trading ecosystem of Saudi Arabia and providing institutional investors with world-class trading solutions.”

About Virtu Financial
Virtu Financial is comprised of companies and financial services firms that leverage cutting-edge technology to deliver liquidity to the global markets and innovative, transparent trading solutions to our clients. Virtu operates one of the world’s longest-running and most widely used electronic block-trading networks, serving institutional asset managers globally. For more information about Virtu’s POSIT block indications network and other workflow tools, please visit our client solutions page at virtu.com.

For more information, please contact:
Matt Sandberg
Investor Relations
investor_relations@virtu.com

Petri Darby
Media
media@virtu.com

–        Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits

–      Independent Cleveland Clinic cardio-oncology evaluation supports continued clinical development of Annamycin as a potentially safer anthracycline

HOUSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced the publication of a peer-reviewed analysis of the cardiac safety of Annamycin (also known as L-Annamycin or naxtarubicin) in Frontiers in Cardiovascular Medicine. The publication, titled “Cardiac safety of L-Annamycin: a pooled analysis of five clinical trials,” reports cardiac safety findings from 90 patients treated across five clinical trials in acute myeloid leukemia (AML) and metastatic soft tissue sarcoma (STS).

The analysis was independently evaluated by a cardio-oncology laboratory at Cleveland Clinic and found no clinical or subclinical evidence of treatment-related cardiotoxicity, including at cumulative Annamycin exposures exceeding traditional lifetime limits for conventional anthracyclines.

“Publication of this comprehensive pooled analysis in a peer-reviewed cardiovascular medicine journal provides additional validation of the cardiac safety profile we have observed with Annamycin across our clinical development program,” said Walter Klemp, Chairman and Chief Executive Officer of Moleculin. “For decades, the clinical utility of anthracyclines has been limited by cumulative cardiotoxicity and associated lifetime dose limits. The absence of detectable cardiac toxicity in patients receiving cumulative doses of Annamycin beyond those traditional thresholds supports our continued development of Annamycin and its potential to address an important limitation of the anthracycline class.”

Pooled Analysis Evaluates Cardiac Safety Across Five Clinical Trials

The publication evaluated cardiac safety data from five sponsor- and investigator-initiated clinical trials, including three trials in AML and two trials in metastatic STS. Across the five studies, 90 patients received Annamycin, with paired echocardiographic data available for 78 patients.

Key findings from the pooled analysis include:

• No significant change in cardiac function: Mean LVEF was 60.6% at baseline compared with 60.0% following treatment, with no statistically significant difference (p=0.84).
• No relationship between cumulative dose and change in LVEF: The analysis found no association between cumulative Annamycin exposure and changes in LVEF.
• No relationship between age and change in LVEF: Patient age was not associated with changes in LVEF.
• No treatment-related cardiotoxicity identified: Serial ECGs, cardiac biomarkers including troponin I/T, and global longitudinal strain assessments showed no evidence of treatment-related cardiotoxicity.
• High cumulative exposure: Patients received a median cumulative Annamycin dose of 660 mg/m², with findings observed despite cumulative exposures exceeding conventional anthracycline lifetime limits.

The authors concluded that Annamycin was not associated with clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline thresholds and that the findings support continued clinical evaluation of Annamycin as a potentially safer anthracycline platform.

Anthracyclines are among the most widely used and effective classes of cancer medicines, but their use can be limited by cumulative, dose-dependent cardiotoxicity. These cardiac risks can restrict treatment intensity, limit retreatment options and prevent some patients from receiving additional anthracycline therapy.

Annamycin is a fundamentally re-engineered anthracycline designed to maintain the antitumor activity of the anthracycline class while addressing the cardiotoxicity associated with conventional agents. Its liposomal formulation was developed to optimize tissue distribution and reduce cardiac exposure.

The newly published article builds upon previously presented clinical data demonstrating a lack of detectable cardiotoxicity with Annamycin despite cumulative exposure levels substantially exceeding conventional anthracycline limits. Moleculin previously reported that the pooled analysis included 90 patients across five completed clinical trials, with independent cardiac review conducted through the Cleveland Clinic Division of Cardiovascular Medicine.

Annamycin is currently being evaluated in Moleculin’s MIRACLE clinical development program for patients with relapsed or refractory AML.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 2/3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML, the potential immune-mediated mechanism of action of Annamycin, the relevance of preclinical findings in pancreatic cancer to the treatment of human disease, and the potential for Annamycin to be combined with other agents. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

–        Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits

–      Independent Cleveland Clinic cardio-oncology evaluation supports continued clinical development of Annamycin as a potentially safer anthracycline

HOUSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced the publication of a peer-reviewed analysis of the cardiac safety of Annamycin (also known as L-Annamycin or naxtarubicin) in Frontiers in Cardiovascular Medicine. The publication, titled “Cardiac safety of L-Annamycin: a pooled analysis of five clinical trials,” reports cardiac safety findings from 90 patients treated across five clinical trials in acute myeloid leukemia (AML) and metastatic soft tissue sarcoma (STS).

The analysis was independently evaluated by a cardio-oncology laboratory at Cleveland Clinic and found no clinical or subclinical evidence of treatment-related cardiotoxicity, including at cumulative Annamycin exposures exceeding traditional lifetime limits for conventional anthracyclines.

“Publication of this comprehensive pooled analysis in a peer-reviewed cardiovascular medicine journal provides additional validation of the cardiac safety profile we have observed with Annamycin across our clinical development program,” said Walter Klemp, Chairman and Chief Executive Officer of Moleculin. “For decades, the clinical utility of anthracyclines has been limited by cumulative cardiotoxicity and associated lifetime dose limits. The absence of detectable cardiac toxicity in patients receiving cumulative doses of Annamycin beyond those traditional thresholds supports our continued development of Annamycin and its potential to address an important limitation of the anthracycline class.”

Pooled Analysis Evaluates Cardiac Safety Across Five Clinical Trials

The publication evaluated cardiac safety data from five sponsor- and investigator-initiated clinical trials, including three trials in AML and two trials in metastatic STS. Across the five studies, 90 patients received Annamycin, with paired echocardiographic data available for 78 patients.

Key findings from the pooled analysis include:

• No significant change in cardiac function: Mean LVEF was 60.6% at baseline compared with 60.0% following treatment, with no statistically significant difference (p=0.84).
• No relationship between cumulative dose and change in LVEF: The analysis found no association between cumulative Annamycin exposure and changes in LVEF.
• No relationship between age and change in LVEF: Patient age was not associated with changes in LVEF.
• No treatment-related cardiotoxicity identified: Serial ECGs, cardiac biomarkers including troponin I/T, and global longitudinal strain assessments showed no evidence of treatment-related cardiotoxicity.
• High cumulative exposure: Patients received a median cumulative Annamycin dose of 660 mg/m², with findings observed despite cumulative exposures exceeding conventional anthracycline lifetime limits.

The authors concluded that Annamycin was not associated with clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline thresholds and that the findings support continued clinical evaluation of Annamycin as a potentially safer anthracycline platform.

Anthracyclines are among the most widely used and effective classes of cancer medicines, but their use can be limited by cumulative, dose-dependent cardiotoxicity. These cardiac risks can restrict treatment intensity, limit retreatment options and prevent some patients from receiving additional anthracycline therapy.

Annamycin is a fundamentally re-engineered anthracycline designed to maintain the antitumor activity of the anthracycline class while addressing the cardiotoxicity associated with conventional agents. Its liposomal formulation was developed to optimize tissue distribution and reduce cardiac exposure.

The newly published article builds upon previously presented clinical data demonstrating a lack of detectable cardiotoxicity with Annamycin despite cumulative exposure levels substantially exceeding conventional anthracycline limits. Moleculin previously reported that the pooled analysis included 90 patients across five completed clinical trials, with independent cardiac review conducted through the Cleveland Clinic Division of Cardiovascular Medicine.

Annamycin is currently being evaluated in Moleculin’s MIRACLE clinical development program for patients with relapsed or refractory AML.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 2/3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML, the potential immune-mediated mechanism of action of Annamycin, the relevance of preclinical findings in pancreatic cancer to the treatment of human disease, and the potential for Annamycin to be combined with other agents. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com